



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW

Robert Geerme Sterne
Jorge A. Goldstein
David C.S. Connell
Robert W. Esmond
Tary-Gene G. Durkin
Michael A. Cimbal
Michael B. Ray
Robert E. Spital
Eric K. Steffe
Michael G. Lee
John M. Covert
Robert C. Miranig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Hevey
Edna L. Elson
Donald R. Banowitz

Peter A. Jackson
Brian J. Del Buono
Mark Fox Evans
Vincent L. Capuano
Elizabeth J. Joanes
Michael D. Specter
Kevin W. McCabe
Glenn J. Perry
Edward W. Wee
Grant E. Reed
Virgil Lee Beason
Theodore A. Wood
Joseph S. Donoff
Jason D. Eisenberg
Tacy L. Muller
Jon E. Wright
Lukeme M. DeGarcia
Ann E. Summerfield
Helene C. Carlson

Cynthia M. Boschez
Timothy A. Doyle
Gaby L. Longplaceth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shamoa A. Carroll
Ambar F. Khal
Michelle K. Hakubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
Young Tang
Christopher J. Walsh
W. Blaise Coblenz
James J. Roll
John I. Hagan
Mark W. Rygiel

Michael R. Malek
Carla Ji-Eun Kim
Doyle A. Silver
Ulrike Winstler
Bryan L. Skelton
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozer
Alexandra K. Pechhold
Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Karinna Nijjan Pei Quach
Julie A. Heider
Mina Mukherjee

Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brantley
Steven C. Oppenheimer
Aaron S. Lukas
Guzan Kulkarna

Of Counsel
Edward L. Kessler
Kenneth C. Bass III
Manny C. Goffine
Christopher P. Wrist

*Admitted only in Maryland
*Admitted only in Virginia
*Practice limited to
Federal Agencies

June 14, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8658
INTERNET ADDRESS:
DNEVRIVY@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1615

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/531,049; § 371 Date: January 17, 2006
(U.S. Nat'l Phase of Appl. No. PCT/CN2002/000728)
For: **A Natural Compound for Prevention and Treatment
of Diabetes, Process for Preparing the Same, and
Pharmaceutical Use Thereof (as amended)**
Inventors: **LIANG et al.**
Our Ref: 2108.0060000/MAC/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. One page of Form PTO/SB/08B listing four documents (NPL6-NPL9); and
3. Copies of documents as cited on Form PTO/SB/08B.


The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Daniel J. Nevrivy
Agent for Applicants
Registration No. 59,118

MAC/DJN/dbj

Enclosures
Sternes Kessler, Goldstein & Fox P.L.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2946 f j.doc